ArticleJugan geon-gang gwa jilbyeong2024
[Prevalence of Recent COVID-19 Variants and Cell-based Omicron KP.3 Infectivity Analysis].
Article in Jugan geon-gang gwa jilbyeong, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the outbreak of the coronavirus disease (COVID-19) pandemic in 2019, the Korea Disease Control and Prevention Agency (KDCA) has been conducting genomic surveillance using whole-genome sequencing to monitor SARS-CoV-2 variants in the Republic of Korea (ROK). Since the JN.1 lineage, derived from BA.2.86, was first detected in ROK in November 2023, the proportion of various JN.1 sub-lineages has continued to increase, with KP.3 accounting for 60.9% as of August 2024. In particular, the KP.3 sub-lineages with the highest shares were identified as KP.3.3.1 (22.3%), KP.3.3 (14.0%), and KP.3.1.1 (11.1%). We compared cell-based infectivity and viral replication among recently circulating JN.1, KP.2, and KP.3. KP.3 showed the highest viral shedding rate up to 48 hours, especially at 24 hours, when it was approximately 67 times higher than that of JN.1 and 23 times higher than that of KP.2. Although there was little difference in peak viral replication among JN.1, KP.2, and KP.3, that of KP.3 was approximately 66 and 16 times higher than that of JN.1 and KP.2, respectively, at 24 hours. We hypothesize that the higher initial infectious virus shedding and viral replication of KP.3 compared to those of JN.1 and KP.2 may have contributed to the increase in transmission and cases. The KDCA will continue close monitoring based on whole-genome sequencing to identify the prevalence of variants in ROK, characterize new variants, and provide scientific evidence to guide the COVID-19 response in the country.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.